| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei |
2013-001445-13: Assessment of the early bronchodilation of Glycopyrronium bromide compared to Tiotropium in patients with moderate to severe COPD |
|
|
| Not yet recruiting | 4 | 150 | Europe | Glycopyrronium bromide, Spiriva Handihaler, NVA237, Inhalation powder, hard capsule, Seebri Breezhaler, Spiriva Handihaler | Novartis Pharma GmbH, Novartis Pharma GmbH | Chronic Obstructive Pulmonary Disease (COPD), COPD is a chronic condition of the lungs which causes people to suffer symptoms such as shortness of breath and coughing., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2021-004972-32: Pharmacokinetics, pharmacodynamics, safety and tolerability of glycopyrronium (bromide) in children (6 to less than 12 years) with asthma. Farmacocinética, farmacodinámica, seguridad y tolerabilidad de bromuro de glicopirronio en niños con asma (de 6 a menos de 12 años de edad). |
|
|
| Ongoing | 2 | 42 | Europe, RoW | Glycopyrronium bromide 25 μg of active moiety in the capsule, Glycopyrronium bromide 12.5 μg of active moiety in the capsule, NVA237, Inhalation powder, hard capsule, Seebri Breezhaler | Novartis Farmacéutica, S.A., Novartis Pharma AG, Novartis Pharma AG | Asthma Asma, Asthma Asma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT05222529 / 2021-004972-32: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma |
|
|
| Recruiting | 2 | 42 | Europe, RoW | Glycopyrronium bromide 25ug, NVA237, Placebo, Glycopyrronium bromide 12.5ug | Novartis Pharmaceuticals, Novartis Pharma AG | Asthma | 06/25 | 06/25 | | |
| pirenzepine topical (WST-057) / WinSanTor |
NCT05005078: A 16-Week Study of Pirenzepine or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy in Patients With HIV |
|
|
| Completed | 2 | 16 | US | WST-057, Placebo | WinSanTor, Inc | HIV Associated Polyneuropathy | 01/23 | 01/23 | | |
NCT05488873: A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy |
|
|
| Active, not recruiting | 2 | 60 | US | WST-057 Active, Active, Placebo | WinSanTor, Inc | Chemotherapy-induced Peripheral Neuropathy | 04/26 | 05/26 | | |
ACTRN12617000535370p: A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Safety, Tolerability and Pharmacokinetic Study of Topical Pirenzepine in Healthy Volunteers |
|
|
| Not yet recruiting | 1 | 24 | | | WinSanTor Australia Pty Ltd, WinSanTor Australia Pty Ltd | Diabetic Peripheral Neuropathy | | | | |
ACTRN12617000535370: A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Safety, Tolerability and Pharmacokinetic Study of Topical Pirenzepine in Healthy Volunteers |
|
|
| Not yet recruiting | 1 | 24 | | | WinSanTor Australia Pty Ltd, WinSanTor Australia Pty Ltd | Diabetic Peripheral Neuropathy | | | | |
| Biliting (bencycloquidium bromide pressurized metered dose inhaler) / YinGu Pharma |
NCT05038202: Study of Bencycloquidium Bromide Nasal Spray in the Treatment of Moderate-severe Persistent Allergic Rhinitis |
|
|
| Active, not recruiting | 4 | 450 | RoW | Bencycloquidium Bromide Nasal Spray, BILITING, Mometasone Furoate Aqueous Nasal Spray, NASONEX | Yingu Pharmaceutical Co., Ltd | Allergic Rhinitis | 04/24 | 06/24 | | |
ChiCTR2000030924: A Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled Trial for Effective and Safe of Bencycloquidium Bromide Nasal Spray in the treatment of Persistent Allergic Rhinitis |
|
|
| Completed | 3 | 708 | | Using Bencycloquidium Bromide Nasal Spray 90ug per nastril, 4 times a day ;Using placebo in the same way as treatment group | West China Hospital, Sichuan University; Silver Valley Pharmaceutical co., LTD, Silver Valley Pharmaceutical co., LTD | Persistent allergic rhinitis | | | | |
ChiCTR1900020497: Tolerability and Pharmacokinetics of Bencycloquidium Bromide Inhalation in Healthy Chinese Volunteers |
|
|
| Recruiting | 1 | 84 | | Bencycloquidium Bromide pressurized metered dose inhaler (pMDI) | West China Hospital, Sichuan University; YINGU Pharmaceutical Co. Ltd, YINGU Pharmaceutical Co. Ltd | COPD | | | | |
| PIPE-307 / Contineum Therap, J&J |
VISTA, NCT06083753: Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects with Relapsing-Remitting Multiple Sclerosis |
|
|
| Recruiting | 2 | 168 | US | PIPE-307 Dose A, PIPE-307 Dose B, Placebo | Contineum Therapeutics | Relapsing Remitting Multiple Sclerosis | 08/25 | 09/25 | | |
| benztropine / Generic mfg. |
2022-002780-30: Efficacy of patient education and duloxetine, alone and in combination, for patients with multiorgan bodily distress syndrome: a partial-factorial randomized controlled trial Patientundervisning og medicinsk behandling (duloxetin/aktiv placebo) til patienter med svær funktionel lidelse: et randomiseret, kontrolleret forsøg |
|
|
| Not yet recruiting | 4 | 212 | Europe | Cymbalta, Benztropine, Capsule, Tablet, Cymbalta, Benztropine | Aarhus University Hospital, The Research Clinic for Functional Disorders and Psychosomatics, The Tryg Foundation | Multiorgan Functional somatic disorders (FSD) / bodily disstress syndrome (BDS) multiorgan Funktionel lidelse, Functional somatic disorder Funktionel lidelse, Not possible to specify | | | | |
EDULOX, NCT06232473: Patient Education and Duloxetine, Alone and in Combination, for Patients With Multisystem Functional Somatic Disorder |
|
|
| Recruiting | 4 | 424 | Europe | Patient Education, Duloxetine, Cymbalta, SNRI, Benztropine Mesylate 0.5 MG and passive placebo RAP, Enhanced usual care | Aarhus University Hospital, Central Denmark Region, University of Aarhus, Vejle Hospital, Aalborg University Hospital, TrygFonden, Denmark, Independent Research Fund Denmark | Functional Disorder | 11/27 | 11/29 | | |
